Summary of Study ST001047

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000699. The data can be accessed directly via it's Project DOI: 10.21228/M8B10B This work is supported by NIH grant, U2C- DK119886.


Show all samples  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST001047
Study Title1H-NMR urinary metabolomic profiling for diagnosis of gastric cancer.
Study SummaryBackground: Metabolomics has shown promise in gastric cancer (GC) detection. This research sought to identify whether GC has a unique urinary metabolomic profile compared with benign gastric disease (BN) and healthy (HE) patients. Methods: Urine from 43 GC, 40 BN, and 40 matched HE patients was analysed using 1H nuclear magnetic resonance (1H-NMR) spectroscopy, generating 77 reproducible metabolites (QC-RSD <25%). Univariate and multivariate (MVA) statistics were employed. A parsimonious biomarker profile of GC vs HE was investigated using LASSO regularised logistic regression (LASSO-LR). Model performance was assessed using Receiver Operating Characteristic (ROC) curves. Results: GC displayed a clear discriminatory biomarker profile; the BN profile overlapped with GC and HE. LASSO-LR identified three discriminatory metabolites: 2-hydroxyisobutyrate, 3-indoxylsulfate, and alanine, which produced a discriminatory model with an area under the ROC of 0.95. Conclusions: GC patients have a distinct urinary metabolite profile. This study shows clinical potential for metabolic profiling for early GC diagnosis.
University of Alberta
Last NameBroadhurst
First NameDavid
AddressDepartment of Medicine, 4126A Katz Group Centre for Pharmacy & Health, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Phone+61 8 6304 2705
Submit Date2018-09-03
PublicationsChan, A. W., Mercier, P., Schiller, D., Bailey, R., Robbins, S., Eurich, D. T., Sawyer, M. B., Broadhurst, D. (2016). 1H-NMR urinary metabolomic profiling for diagnosis of gastric cancer. British Journal of Cancer, 114(1), 59-62. doi:10.1038/bjc.2015.414
Raw Data File Type(s)d
Analysis Type DetailNMR
Release Date2018-10-10
Release Version1
David Broadhurst David Broadhurst application/zip

Select appropriate tab below to view additional metadata details:


Collection ID:CO001081
Collection Summary:Midstream urine samples were collected from 43 GC, 40 BN, and 40 HE patients from January 2009 to December 2014 from three hospitals in Edmonton, Canada. GC samples were collected prior to chemoradiotherapy and surgery. All patients provided written informed consent. Ethics approval was obtained from the Health Research Ethics Board at the University of Alberta. Inclusion criteria for cancer patients were: biopsy-confirmed diagnosis of GC, age >=18 years, and no metastases on their staging computed tomography scans. BN patients had to experience gastrointestinal symptoms (such as haematemesis or epigastric discomfort) and must have endoscopic evidence within the past 6 months of consent that symptoms were not due to a malignant cause. BN patients had the following conditions: gastritis, gastro- oesophageal reflux disease (GORD), portal hypertensive gastro- pathy, varices, gastritis, ulcers, and polyps. HE controls had no declared history of cancer and no gastrointestinal symptoms. Groups were matched on age, gender, and BMI. Exclusion criteria included: breastfeeding, pregnancy, significant cardiac disease with New York Heart Association XClass II, systemic infection, prior cancer, and glomerular filtration rate 30 ml min ^-1.
Sample Type:Urine